EHOC

Registration & Accommodation

Programs




Leukemia Research

Committees

General Information

Draft Program


How Hematology Changed During the Days in the Life of Eliezer Rachmilewitz
Lessons Learned From CML (Inaugural Lecture Dedicated to Eliezer Rachmilewitz)
Von Willebrand Disease, Laboratory Issues
Tumor Evolution in Genomic Era and Darwin
The Role of T Cell Immunotherapy in the Management of Aggressive Lymphomas
Best Abstract Presentation (Eliezer Rachmilewitz Prize) - Analysis of Genetic Abnormalities in Newly Diagnosed Acute Lymphoblastic Leukemia Patients at King Faisal Specialist Hospital & Research Centre
Paroxysmal Nocturnal Hemoglobinuria
Prognostic Molecular Markers in MDS
Current Treatment of MDS
New Therapies in MDS
Current Treatment of Myeloproliferative Neoplasms
Jak2 Inhibıtors and What Comes Next for Patients with
BCR-ABL1- Negatıive Myeloproliferative Neoplasms
Molecular Markers and New Prognostic Scores in MPNs
First Line Therapy for Multiple Myeloma
Treatmens in Relapsed / Refractory Multiple Myeloma
New Drugs for Multiple Myeloma
AML Therapy: What is Essential and What is Investigational
Molecular Characterization and Follow Up in AML, Practical Issues
APL: A Special Kind of AML with a Different Treatment
Significant Milestones in CML Treatment - NOVARTIS SATELLITE
ALL Therapy: Essential Elements for Proper Treatment
Diagnostic And Prognostic Markers in ALL
New Monoclonal Antibodies in ALL
Debate: Ph-Positive Acute Lymphoblastic Leukemia: Will We Still Need Chemotherapy and Stem cell Transplantion? Yes
Debate: Ph-Positive Acute Lymphoblastic Leukemia: Will We Still Need Chemotherapy and Stem cell Transplantion? No
New Therapeutic Options in CLL
New Biomarkers in CLL
Future Goals in CLL Therapy
Apheresis in the Management of Hematological Disorders Using the Therapeutic Apheresis Guidelines of the American Society for Apheresis
Medical Decision Making in Apheresis Medicine: When the Guidelines Do Not Cover Your Patient’s Condition
Recent Advances in the Management of Thrombotic Thrombocytopenic Purpura (TTP) and Their Effect on the Role of Apheresis in Its Treatment
Impact of High-Risk Additional Chromoseme Aberration on Survival and Blast Crisis
Are the Results that We Can Obtain with Imatinib All the Same in the World?
Treatment Discontinuation in Chronic Myeloid Leukemia, When and How ?
Response Monitoring in Chronic Myeloid Leukemia in the TFR Era
New Era with Carfilzomib in the Treatment of Relapsed / Refractory Multiple Myeloma
New Treatment Approaches in ALL Treatment
State of the Art of NHL Therapy
A Translational Perspective on Diffuse Large B-Cell Lymphoma
New Approaches in Marginal Zone Lymphoma
Mantle Cell Lymphoma, Blastic Variant; Diagnosis, Treatment
Essential Treatments of NHL
First-Line Treatment of Hodgkin Lymphoma
Transplant in NHL; When? To Whom?
CLL Treatment Landscape in R/R CLL Patients in Scope of BCL-2 Inhibition
Chronic Lymphocytic Leukemia Old and New Treatments
When and Why Chemo-Free Regimens in Mantle Cell Lymphoma
Cancer Immunotherapy: Monoclonal antibodies from laboratory reagents to therapy
Single cell surface proteomics for discovery of therapeutic targets
Impact of Posttransplant Hypomethelating Agnets on Cumulative Incidence Risk of Relapse After Allotransplants for Myeloid Maligancies
From Allogenic Transplantation to Precision Immune Therapy: The Role of Effector Cells
Antifungal Management in Febril Neutropenia